| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.003 | 1 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.36 | 6e-27 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.34 | 4e-14 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.27 | 2e-13 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-10 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-10 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-09 |